IGC Pharma Adds New York Site for Alzheimer’s Disease Trial
- Sponsor: IGC Pharma
- Drug: IGC-AD1
- New Site: Integrative Clinical Trials
- Location: Brooklyn, New York
- Target: Agitation in Alzheimer’s
IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, US, as a new site evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.
IGC incorporates AI to optimise trials, enhance patient targeting, and accelerate drug discovery. The ongoing expansion of the CALMA trial demonstrates IGC Pharma’s efforts to facilitate patient enrolment and ensure comprehensive clinical monitoring during the study.
New Site Expertise: Integrative Clinical Trials
Integrative Clinical Trials conducts studies across a broad range of central nervous system (CNS) disorders, including mild cognitive impairment and Alzheimer’s. The site is led by principal investigator Dr Inna Yuryev-Golger, who has more than ten years of experience in clinical research, and Bella Yevseva, who serves as clinical trial coordinator.
The centre enhances IGC Pharma’s access to a diverse patient population in a major metropolitan area. The company stated that bringing in sites with CNS experience is central to supporting enrolment and patient engagement for the ongoing study.
About IGC-AD1 and Trial Design
IGC-AD1 is an investigational cannabinoid-based therapy being studied in a double-blind, placebo-controlled, randomised Phase II clinical trial for patients experiencing agitation related to Alzheimer’s.
— Ram Mukunda, CEO of IGC Pharma
Pipeline and AI Integration
IGC develops therapies for Alzheimer’s and metabolic disorders using AI. Its pipeline includes:
- IGC-AD1 (Agitation in Alzheimer's)
- TGR-63 (Targeting amyloid plaques)
- Early-stage programmes focused on tau proteins, metabolic dysfunctions, and neurodegeneration.
In 2024, IGC Pharma reported the enrolment of two subjects at Neurostudies, a clinical research site in Port Charlotte, Florida, US, for its Phase II trial of IGC-AD1 to treat agitation in Alzheimer’s.
